BRPI1006790A2 - método para desenvolver uma composição líquida a ser aplicada na pele como uma espuma e uma composição que pode ser aplicada topicamente - Google Patents

método para desenvolver uma composição líquida a ser aplicada na pele como uma espuma e uma composição que pode ser aplicada topicamente

Info

Publication number
BRPI1006790A2
BRPI1006790A2 BRPI1006790A BRPI1006790A BRPI1006790A2 BR PI1006790 A2 BRPI1006790 A2 BR PI1006790A2 BR PI1006790 A BRPI1006790 A BR PI1006790A BR PI1006790 A BRPI1006790 A BR PI1006790A BR PI1006790 A2 BRPI1006790 A2 BR PI1006790A2
Authority
BR
Brazil
Prior art keywords
composition
foam
developing
skin
liquid composition
Prior art date
Application number
BRPI1006790A
Other languages
English (en)
Inventor
G Seigfried Bernd
Original Assignee
Mika Pharma Ges Für Die Entw Und Vermarktung Pharmazeutischer Produkte Mbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mika Pharma Ges Für Die Entw Und Vermarktung Pharmazeutischer Produkte Mbh filed Critical Mika Pharma Ges Für Die Entw Und Vermarktung Pharmazeutischer Produkte Mbh
Publication of BRPI1006790A2 publication Critical patent/BRPI1006790A2/pt
Publication of BRPI1006790B1 publication Critical patent/BRPI1006790B1/pt
Publication of BRPI1006790B8 publication Critical patent/BRPI1006790B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A61K9/122—Foams; Dry foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/10—Expectorants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nutrition Science (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Transplantation (AREA)
  • Endocrinology (AREA)
BRPI1006790A 2009-07-24 2010-07-16 método para desenvolver uma composição farmacêutica líquida a ser aplicada na pele como uma espuma e composição adequada para uso tópico BRPI1006790B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102009034603.1 2009-07-24
DE102009034603 2009-07-24
PCT/DE2010/000818 WO2011009436A2 (de) 2009-07-24 2010-07-16 Verfahren zur entwicklung einer als schaum auf die haut zu applizierende flüssige zusammensetzung sowie eine topisch applizierbare zusammensetzung

Publications (3)

Publication Number Publication Date
BRPI1006790A2 true BRPI1006790A2 (pt) 2017-05-02
BRPI1006790B1 BRPI1006790B1 (pt) 2020-10-20
BRPI1006790B8 BRPI1006790B8 (pt) 2021-05-25

Family

ID=43384132

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1006790A BRPI1006790B8 (pt) 2009-07-24 2010-07-16 método para desenvolver uma composição farmacêutica líquida a ser aplicada na pele como uma espuma e composição adequada para uso tópico

Country Status (14)

Country Link
US (4) US20110269704A1 (pt)
EP (1) EP2387391B1 (pt)
JP (1) JP2013500239A (pt)
BR (1) BRPI1006790B8 (pt)
CA (1) CA2752849C (pt)
DE (1) DE102010027315A1 (pt)
ES (1) ES2622097T3 (pt)
HR (1) HRP20170376T1 (pt)
MX (1) MX2011008660A (pt)
PL (1) PL2387391T3 (pt)
PT (1) PT2387391T (pt)
RU (1) RU2532027C2 (pt)
SI (1) SI2387391T1 (pt)
WO (1) WO2011009436A2 (pt)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2752849C (en) 2009-07-24 2014-07-08 Bernd G. Seigfried Liquid compositions capable of foaming and including active agents, and methods for making or developing same
EP2547323B1 (en) 2010-03-17 2016-01-27 Novaliq GmbH Pharmaceutical composition for treatment of increased intraocular pressure
EP2444063A1 (en) 2010-10-20 2012-04-25 Novaliq GmbH Liquid pharmaceutical compositions for the delivery of active ingredients
EP2462921A1 (en) 2010-11-11 2012-06-13 Novaliq GmbH Liquid pharmaceutical compositions for the treatment of a posterior eye disease
DE102010055252A1 (de) * 2010-12-20 2012-06-21 Mika Pharma Gesellschaft Für Die Entwicklung Und Vermarktung Pharmazeutischer Produkte Mbh Verfahren zur Entwicklung einer als Schaum auf die Haut zu applizierende flüssige Zusammensetzung sowie eine topisch applizierbare Zusammensetzung
EP2714008B1 (en) * 2011-05-25 2016-12-14 Novaliq GmbH Pharmaceutical composition for administration to nails
CA2834855C (en) 2011-05-25 2020-12-29 Novaliq Gmbh Topical pharmaceutical composition based on semifluorinated alkanes
DK2806886T3 (en) 2012-01-23 2017-06-06 Novaliq Gmbh STABILIZED PROTEIN COMPOSITIONS BASED ON SEMIFLUORED ALKANES
US20130309215A1 (en) * 2012-05-15 2013-11-21 Mika Pharma Gesellschaft Fur Die Entwicklung Und Vermarktung Pharmazeutischer Produkte Mbh Pharmaceutical composition
DE102013004199A1 (de) * 2012-05-15 2013-11-21 Mika Pharma Gesellschaft Für Die Entwicklung Und Vermarktung Pharmazeutischer Produkte Mbh Pharmazeutische Zusammensetzung
MX363182B (es) 2012-09-12 2019-03-13 Novaliq Gmbh Composiciones que comprenden mezclas de alcanos semifluorados.
AU2013314303B2 (en) 2012-09-12 2018-01-18 Novaliq Gmbh Semifluorinated alkane compositions
JP6503349B2 (ja) 2013-07-23 2019-04-17 ノバリック ゲーエムベーハー 安定化された抗体組成物
US9579257B2 (en) 2013-08-20 2017-02-28 Anutra Medical, Inc. Haptic feedback and audible output syringe
CA2875384A1 (en) 2013-12-20 2015-06-20 AntiOP, Inc. Intranasal naloxone compositions and methods of making and using same
USD750768S1 (en) 2014-06-06 2016-03-01 Anutra Medical, Inc. Fluid administration syringe
USD774182S1 (en) 2014-06-06 2016-12-13 Anutra Medical, Inc. Anesthetic delivery device
USD763433S1 (en) 2014-06-06 2016-08-09 Anutra Medical, Inc. Delivery system cassette
US10265268B2 (en) * 2014-12-24 2019-04-23 Pola Pharma Inc. External composition for screen foamers
EP3495023B1 (en) 2015-09-30 2020-04-22 Novaliq GmbH Semifluorinated compounds and their compositions
US11154513B2 (en) 2015-09-30 2021-10-26 Novaliq Gmbh Semifluorinated compounds
RU2609197C1 (ru) * 2015-12-15 2017-01-30 Иштимер Шагалиевич Хурамшин Раствор для декальцинации при лечении заболеваний опорно-двигательного аппарата
WO2017220625A1 (en) 2016-06-23 2017-12-28 Novaliq Gmbh Topical administration method
EP3515420B1 (en) 2016-09-22 2023-11-08 Novaliq GmbH Pharmaceutical compositions for use in the therapy of blepharitis
KR20190057338A (ko) 2016-09-23 2019-05-28 노바리크 게엠베하 시클로스포린을 포함하는 안과 조성물
AU2018253944B2 (en) 2017-04-21 2022-09-15 Dermaliq Therapeutics, Inc. Iodine compositions
EP3621601A1 (en) 2017-05-12 2020-03-18 Novaliq GmbH Pharmaceutical compositions comprosing semifluorinated alkanes for the treatment of contact lense-related conditions
RU2659418C1 (ru) * 2017-08-24 2018-07-02 Закрытое Акционерное Общество "Производственная Фармацевтическая Компания Обновление" Антибактериальная композиция для доставки Грамицидина С к очагу местного воспаления, способ приготовления антибактериальной композиции для доставки Грамицидина С к очагу местного воспаления, способ доставки Грамицидина С к очагу местного воспаления
US11723861B2 (en) 2017-09-27 2023-08-15 Novaliq Gmbh Ophthalmic compositions comprising latanoprost for use in the treatment of ocular diseases
US11896559B2 (en) 2017-10-04 2024-02-13 Novaliq Gmbh Opthalmic compositions comprising F6H8
RU2697829C2 (ru) * 2017-11-01 2019-08-21 Общество с ограниченной ответственностью "Технофарм" Фармацевтическая композиция, содержащая нитрофурал, в форме шипучих таблеток (варианты)
WO2019166631A1 (en) 2018-03-02 2019-09-06 Novaliq Gmbh Pharmaceutical compositions comprising nebivolol
CA3111870C (en) 2018-09-27 2022-04-12 Novaliq Gmbh Topical sunscreen formulation
ES2974839T3 (es) 2018-10-12 2024-07-01 Novaliq Gmbh Composición oftálmica para el tratamiento de la enfermedad de ojos secos
RU2696568C1 (ru) * 2019-03-20 2019-08-05 Общество с ограниченной ответственностью "Технофарм" Фармацевтическая композиция, содержащая нитрофурал, в форме шипучих таблеток (варианты)
RU2742411C1 (ru) * 2020-10-08 2021-02-05 Георгий Сергеевич Немов Противопсориатическая косметическая композиция в виде геля
EP4359445A1 (en) * 2021-06-21 2024-05-01 Joint Stock Company "Biocad" Isolated bispecific antibody that specifically binds to cd47 and pd-l1
CN114409734B (zh) * 2022-01-25 2023-05-12 四川大学华西医院 一种可诱导局部麻醉药生物矿化的自组装短肽及其制得的长效局部麻醉和镇痛药物制剂

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US510561A (en) * 1893-12-12 John abell
JPS5210457B2 (pt) * 1973-10-24 1977-03-24
JPS5473135A (en) * 1977-11-24 1979-06-12 Kashiwa Kagaku Kogyo Kk Bubble type permanent wave agent
DE3585967D1 (de) 1984-03-08 1992-06-11 Phares Pharma Holland Liposombildende zusammensetzung.
US4863970A (en) 1986-11-14 1989-09-05 Theratech, Inc. Penetration enhancement with binary system of oleic acid, oleins, and oleyl alcohol with lower alcohols
JPH01242521A (ja) * 1988-03-23 1989-09-27 Nikko Kemikaruzu Kk 経皮吸収性を高めた消炎鎮痛薬組成物
DE3824353A1 (de) 1988-07-19 1990-01-25 Paz Arzneimittelentwicklung Verfahren zur trennung von gemischen enantiomerer arylpropionsaeuren
US4975425A (en) * 1989-03-16 1990-12-04 Mobay Corporation Pesticidal and herbicidal foams
US6165500A (en) 1990-08-24 2000-12-26 Idea Ag Preparation for the application of agents in mini-droplets
DE4028906A1 (de) 1990-09-12 1992-03-19 Paz Arzneimittelentwicklung Arzneimittel sowie deren herstellung und deren verwendung bei der bekaempfung von schmerzen und/oder entzuendungen und/oder fieber an tieren und menschen
EP0565713B1 (en) 1990-11-07 1995-03-15 Daiwa Can Company, Limited Bubble spouting pump vessel
IT1247529B (it) * 1991-04-24 1994-12-17 Poli Ind Chimica Spa Composizioni farmaceutiche in forma di schiuma per somministrazione intravaginale, cutanea e orale
DK0521398T3 (da) 1991-07-05 1999-07-05 Rhone Poulenc Rorer Gmbh Phospholipidsammensætning
DE4140184C2 (de) 1991-12-05 1995-12-21 Alfatec Pharma Gmbh Akutform für ein Flurbiprofen enthaltendes Arzneimittel
DE4140172C2 (de) 1991-12-05 1995-12-21 Alfatec Pharma Gmbh Retardform für ein Ibuprofen enthaltendes Arzneimittel
DE4140185C2 (de) 1991-12-05 1996-02-01 Alfatec Pharma Gmbh Ein 2-Arylpropionsäurederivat in Nanosolform enthaltendes Arzneimittel und seine Herstellung
DE4140183C2 (de) 1991-12-05 1995-12-21 Alfatec Pharma Gmbh Retardform für ein Flurbiprofen enthaltendes Arzneimittel
DE4140179C2 (de) 1991-12-05 1995-12-21 Alfatec Pharma Gmbh Akutform für ein Ibuprofen enthaltendes Arzneimittel
DE4216756C2 (de) 1992-05-21 1994-08-25 Pharmatrans Sanaq Ag 2-Arylpropionsäure-Zubereitungen und Verfahren zu ihrer Herstellung
JPH0669161U (ja) 1993-03-05 1994-09-27 大和製罐株式会社 ポンプ式泡出し容器
DE4313402A1 (de) 1993-04-23 1994-10-27 Hexal Pharma Gmbh Transdermale Wirkstoffzubereitung
US5580491A (en) * 1993-07-13 1996-12-03 Cornell Research Foundation, Inc. Foamable whey protein composition
ES2180599T3 (es) 1994-09-30 2003-02-16 Mika Pharma Ges Fur Die Entwic Composicion farmaceutica.
DE4436352A1 (de) 1994-10-12 1996-04-18 Kay Brune Verfahren zur diagnostischen Beurteilung und Verlaufskontrolle sowie Arzneimittel zur Therapie von Schockzuständen beim Menschen
US5747058A (en) 1995-06-07 1998-05-05 Southern Biosystems, Inc. High viscosity liquid controlled delivery system
DE19520659A1 (de) 1995-06-09 1996-12-12 Mika Pharma Ges Fuer Die Entwi Pharmazeutische Zubereitung zur Therapie und/oder Prophylaxe von durch Viren bedingten Erkrankungen der Haut und/oder der Schleimhaut
EP0914159A1 (de) 1996-07-13 1999-05-12 ratiopharm GmbH Topische phospholipidhaltige aciclovirzubereitung
GB9625589D0 (en) 1996-12-10 1997-01-29 Boots Co Plc Therapeutic agents
DE19716713A1 (de) 1997-04-21 1998-10-22 Paz Arzneimittelentwicklung Arzneimittel, enthaltend Ibuprofenthioester als Hemmer der Nf-kappaB abhängigen Bildung von Mediatoren von Entzündung und Schmerz
US5976566A (en) 1997-08-29 1999-11-02 Macrochem Corporation Non-steroidal antiinflammtory drug formulations for topical application to the skin
DE19740095C2 (de) 1997-09-12 2000-06-08 Cognis Deutschland Gmbh Verfahren zum Bestimmen der Schaumeigenschaften von Tensiden
WO1999016471A1 (fr) 1997-10-01 1999-04-08 Wakamoto Pharmaceutical Co., Ltd. Compositions d'emulsions de type aqueux
WO1999044642A1 (en) 1998-03-05 1999-09-10 Phares Pharmaceutical Research Nv Pharmaceutical compositions and their use
BE1011899A6 (fr) 1998-04-30 2000-02-01 Ucb Sa Compositions pharmaceutiques gelifiables utilisables.
DE19907895A1 (de) 1999-02-24 2000-11-16 Paz Arzneimittelentwicklung Verwendung von R-Arylpropionsäuren zur Herstellung von Arzneimitteln zur Behandlung von Erkrankungen bei Mensch und Tier, welche durch die Hemmung der Aktivierung von NF-kB therapeutisch beeinflußt werden können
DE19925810A1 (de) 1999-06-07 2000-12-14 Paz Arzneimittelentwicklung Anwendung von Verapamil und Verapamilderivaten zur Herstellung von Arzneimitteln mit Glucuronidase hemmender Wirkung
US6309663B1 (en) 1999-08-17 2001-10-30 Lipocine Inc. Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
DE19949922C1 (de) 1999-10-16 2001-05-31 Sita Messtechnik Gmbh Verfahren und Vorrichtung zum Messen der Schaumeigenschaften von Flüssigkeiten
US6582724B2 (en) 1999-12-16 2003-06-24 Dermatrends, Inc. Dual enhancer composition for topical and transdermal drug delivery
US6645520B2 (en) 1999-12-16 2003-11-11 Dermatrends, Inc. Transdermal administration of nonsteroidal anti-inflammatory drugs using hydroxide-releasing agents as permeation enhancers
DE10024413A1 (de) 2000-05-19 2001-12-06 Mika Pharma Gmbh Pharmazeutische und/oder kosmetische Zubereitung
DE10047319A1 (de) 2000-09-25 2002-04-18 Paz Arzneimittelentwicklung Verwendung von R-Arylpropionsäuren zur Herstellung von Arzneimitteln zur Behandlung von Erkrankungen, welche durch die Hemmung der Aktivierung des nukleären Transkriptionsfaktors AP-1 therapeutisch beeinflußt werden können
DE10142996A1 (de) 2001-09-01 2003-03-27 Paz Arzneimittelentwicklung Verwendung von Wirkstoffen mit mu-Opioid-Rezeptor agonistischer Wirkung als Kombinationsarzneimittel zur Krebsbehandlung
FR2829693B1 (fr) * 2001-09-20 2004-02-27 Oreal Creme cosmetique moussante
DE10217555A1 (de) 2002-04-19 2004-02-19 Degussa Bioactives Deutschland Gmbh Physiologisch verträgliche, Phospholipid-haltige, stabile und harte Matrix
US20040105881A1 (en) 2002-10-11 2004-06-03 Gregor Cevc Aggregates with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin
GB0323908D0 (en) * 2003-10-11 2003-11-12 Nupharm Lab Ltd Pharmaceutical foam formulation
US20050220742A1 (en) * 2004-03-31 2005-10-06 Breen Ed V Compositions and methods for maintaining eyelid hygiene
US7971659B2 (en) * 2004-05-05 2011-07-05 Clearwater International, Llc Foamer/sulfur scavenger composition and methods for making and using same
AU2006244386B2 (en) 2005-05-10 2011-12-22 Johnson & Johnson Consumer Companies, Inc. Low-irritation compositions and methods of making the same
US20070160555A1 (en) * 2006-01-09 2007-07-12 Staudigel James A Personal care compositions containing cationically modified starch and an anionic surfactant system
US20070224153A1 (en) * 2006-03-16 2007-09-27 Librizzi Joseph J High-deposition compositions and uses thereof
ATE440598T1 (de) 2007-03-02 2009-09-15 Flamek Corp Ou Analgesische zusammensetzung von topisch angewendeten, nichtsteroiden und entzündungshemmenden arzneimitteln und opioiden
EP3607937A1 (en) 2007-03-22 2020-02-12 Berg LLC Topical formulations having enhanced bioavailability
EP1975224A1 (en) 2007-03-30 2008-10-01 Johnson & Johnson Consumer France SAS Mild, foaming cleansing composition
PL2020221T3 (pl) 2007-06-19 2012-07-31 Neubourg Skin Care Gmbh & Co Kg Kremy DMS (Derma Membrane Structure) w postaci pianki
CA2710318A1 (en) 2007-12-21 2009-07-09 Paz Arzneimittel-Entwicklungsgesellscaft Mbh Drugs as well as their production and use in the treatment of pain-associated neuropathies
US20090162421A1 (en) 2007-12-21 2009-06-25 Paz Arzneimittel-Entwicklungsgesellschaft Mbh Drugs as well as their production and use in the treatment of pain-associated neuropathies
US8652443B2 (en) * 2008-02-14 2014-02-18 Precision Dermatology, Inc. Foamable microemulsion compositions for topical administration
ATE533364T1 (de) 2008-09-25 2011-12-15 Nestec Sa Reduktion der astringenz in zusammensetzungen mit phenolverbindungen
EP2340043A4 (en) 2008-10-31 2012-09-19 Moberg Derma Ab TOPICAL COMPOSITION COMPRISING A COMBINATION OF AT LEAST TWO PENETRATION AGENTS
CA2752849C (en) 2009-07-24 2014-07-08 Bernd G. Seigfried Liquid compositions capable of foaming and including active agents, and methods for making or developing same
US20130309215A1 (en) 2012-05-15 2013-11-21 Mika Pharma Gesellschaft Fur Die Entwicklung Und Vermarktung Pharmazeutischer Produkte Mbh Pharmaceutical composition

Also Published As

Publication number Publication date
EP2387391B1 (de) 2017-01-11
ES2622097T3 (es) 2017-07-05
WO2011009436A3 (de) 2011-09-15
DE102010027315A1 (de) 2011-01-27
PL2387391T3 (pl) 2017-09-29
WO2011009436A2 (de) 2011-01-27
RU2532027C2 (ru) 2014-10-27
US20160022579A1 (en) 2016-01-28
US20180104185A1 (en) 2018-04-19
JP2013500239A (ja) 2013-01-07
HRP20170376T1 (hr) 2017-05-05
RU2011134420A (ru) 2013-02-27
US9693956B2 (en) 2017-07-04
EP2387391A2 (de) 2011-11-23
CA2752849A1 (en) 2011-01-27
US20110059117A1 (en) 2011-03-10
US20110269704A1 (en) 2011-11-03
BRPI1006790B8 (pt) 2021-05-25
CA2752849C (en) 2014-07-08
US9005626B2 (en) 2015-04-14
WO2011009436A9 (de) 2011-03-31
MX2011008660A (es) 2011-09-22
BRPI1006790B1 (pt) 2020-10-20
SI2387391T1 (sl) 2017-04-26
PT2387391T (pt) 2017-04-20

Similar Documents

Publication Publication Date Title
BRPI1006790A2 (pt) método para desenvolver uma composição líquida a ser aplicada na pele como uma espuma e uma composição que pode ser aplicada topicamente
BR112013024025A2 (pt) composição fluida destinada a ser aplicada na pele
BRPI1012626A2 (pt) método e aparelho para possibilitar que uma localização em um espaço de coordenadas seja visualizada
ES2454044B1 (es) Plataforma flotante en tensión de especial aplicación para aprovechamiento eólico
BR112012032172A2 (pt) método para produzir um álcool e composição
BR112015006996A2 (pt) método para reduzir a quantidade de enxofre em uma composição que compreende enxofre, e, composição.
BR112013024028A2 (pt) composição fluida destinada a ser aplicada sobre a pele
BR112013024467A2 (pt) método e composições direcionadas para células adiposas em mamíferos
BR112013018877A2 (pt) composições farmacêuticas que compreendem anticorpos humanos para pcsk9
BRPI0909174A2 (pt) Composição cosméticas para proporcionar peliculas super hidrofóbicas
BR112013011730A2 (pt) composição de oligossacarídeos para tratar doenças da pele
IL236821B (en) Device and method for the application of a liquid compound that hardens to a body part
BR112013008068A2 (pt) método para reduzir o estresse hídrico em plantas
BR112014012753A2 (pt) composição para pele e método de hidratação da pele
CO7010841A2 (es) Proceso para la preparación de un catalizador que puede ser utilizado en hidrotratamiento e hidroconversión
BR112013024959A2 (pt) sn-1(3) monoacilglicerídeos e absorção de lipídeo
BRPI1014362A2 (pt) método e composição para sincronizar o tempo de inseminação
BRPI1013509A2 (pt) método e composição para melhorar a absorção de agentes terapêuticos
BRPI0921804A2 (pt) método assistido por computador apropriado para auxiliar no projeto de uma aeronave
BR112013015781A2 (pt) compostos e métodos para reparação da pele
BR112013007298A2 (pt) método para produzir composição de borracha
BR112014010457A2 (pt) composição cosmética e processos para a fabricação de uma composição cosmética e para recobrir a pele com uma composição cosmética
BR112015004213A2 (pt) caixa de metal desmontável e método para esvaziar uma caixa que é preenchida com um material, em particular um material que é suscetível a deformação
IL239151B (en) Device and method for the application to a part of a body part of a liquid compound that hardens
BRPI1010684A2 (pt) método para determinar o potencial cardiorregenerativo de células mamíferas

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 20/10/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 16/07/2010 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 12A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2679 DE 10-05-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.